AstraZeneca LP v. Amneal Pharmaceuticals LLC
1:15-cv-01056
Overview
Parties
Defendant
Amneal Pharmaceuticals Co. India Private Limited NPE (University / Research)
Represented By
3 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Amneal Pharmaceuticals of New York, LLC Operating Company
Represented By
5 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Amneal Pharmaceuticals LLC Operating Company
Represented By
5 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Plaintiff
AstraZeneca Pharmaceuticals LP NPE (Individual / Inventor)
Represented By
3 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
AstraZeneca UK Limited NPE (University / Research)
Represented By
3 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
AstraZeneca AB NPE (Individual / Inventor)
Represented By
3 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
AstraZeneca LP NPE (Individual / Inventor)
Represented By
6 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 2 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 6,251,910 Asserted | Asserted Patent | View Official Patent → |
| 🌐 PCT International (WIPO) | WO 1999005143 A1 | PCT World Application | View Official Patent → |
AstraZeneca LP v. Watson Laboratories Inc.
AstraZeneca LP v. Prinston Pharmaceutical Inc.
AstraZeneca LP v. Micro Labs Limited
AstraZeneca LP v. InvaGen Pharmaceuticals Inc.
AstraZeneca LP v. Watson Laboratories, Inc.
AstraZeneca LP v. Alembic Pharmaceuticals LTD
AstraZeneca LP v. Mylan Pharmaceuticals Inc.
Patents Involved
There are 5 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6251910
1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
|
Filed: 1998-07-15
Issued: 2001-06-26
|
Expired (Term Ended)
Expires: 2018-07-15
|
|
|
US6525060
Triazolo(4,5-d)pyrimidine compounds
|
Filed: 1999-12-02
Issued: 2003-02-25
|
Expired (Term Ended)
Expires: 2019-12-02
|
|
|
US7250419
Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
|
Filed: 2005-09-21
Issued: 2007-07-31
|
Expired (Term Ended)
Expires: 2025-09-21
|
|
|
US7265124
Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
|
Filed: 2005-10-03
Issued: 2007-09-04
|
Expired (Term Ended)
Expires: 2021-07-09
|
|
|
US8425934
Pharmaceutical compositions
|
Filed: 2007-08-20
Issued: 2013-04-23
|
Active (3.4 yrs remaining)
+971d PTA
Expires: 2030-04-17
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
3
Dispositive
0
Granted
0
Denied
0
Pending / Review
2
Motions by Category
Key Dispositive Motions & Rulings